DEFA14A: Amicus Therapeutics Updates Merger Proxy, Addresses Lawsuits

Amicus Therapeutics filed additional proxy materials to supplement its definitive proxy statement for the BioMarin merger, addressing multiple stockholder lawsuits and updating financial projections.

Summary

• Amicus Therapeutics filed definitive additional materials to supplement its definitive proxy statement dated February 2, 2026, for a special meeting on March 3, 2026.
• The special meeting is to consider and vote upon a proposal to adopt the Agreement and Plan of Merger with BioMarin Pharmaceutical Inc., which would result in Amicus becoming a wholly-owned subsidiary of BioMarin.
• The supplement provides voluntary disclosures to address four stockholder lawsuits (Pathak, Marino, Lawrence, Drulias) alleging material omissions and misleading disclosures in the preliminary and definitive proxy statements.
• Amicus also received a demand to inspect books and records (Section 220 DGCL) and additional demand letters from purported stockholders, all of which Amicus believes are without merit.
• The filing includes updated financial projections (July, November, and December Projections) used by financial advisors Centerview Partners LLC and Goldman Sachs & Co. LLC for their fairness opinions.
• Key updates to the merger background include details on the Transactions Committee formation, initial contact with BioMarin, outreach to other potential strategic partners, and the resolution of litigation with Lupin and Aurobindo regarding generic Galafold.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this filing with caution due to the multiple ongoing stockholder lawsuits challenging the merger, which introduce significant legal and operational risks, despite the company's belief that the claims are without merit.

Positives

• Resolution of Lupin Litigation and Aurobindo Litigation through confidential license agreements, allowing generic Galafold in the US from January 30, 2037.
• The Board of Directors formed a Transactions Committee to efficiently oversee management and evaluate business development opportunities.

Negatives

• Four lawsuits filed by purported stockholders alleging material omissions and misleading disclosures in the proxy statements related to the merger.
• Lawsuits seek injunctive relief to prevent merger consummation, rescission or damages if consummated, and plaintiffs' fees and expenses.
• Receipt of a demand to inspect books and records and additional demand letters from purported stockholders.
• The Board decided not to request an increased offer from BioMarin despite an increase in Amicus's stock price, based on BioMarin's repeated indications of unwillingness to increase.

Risks

• Uncertainties regarding the ability to obtain shareholder approval for the merger.
• Possibility of competing offers for Amicus.
• Risk that various closing conditions for the merger may not be satisfied or waived, including that a governmental entity may prohibit, delay or refuse to grant approval for the consummation of the transactions.
• Effects of the transactions on relationships with employees, other business partners, or governmental entities.
• Difficulty in predicting the timing or outcome of FDA approvals or actions, if any.
• Impact of competitive products and pricing.
• Risk that BioMarin may not realize the potential benefits of the transaction.
• Other business effects, including the effects of industry, economic or political conditions outside of the companies' control.
• Transaction costs and actual or contingent liabilities.
• Additional demands or lawsuits may be filed against Amicus, its Board of Directors, BioMarin, and/or Merger Sub in connection with the transactions.

Future Outlook

The filing primarily focuses on the ongoing merger process and addressing related legal challenges. Forward-looking statements reiterate the parties' ability to satisfy conditions, the expected timetable, and Amicus's plans post-merger, but also highlight risks like obtaining shareholder and governmental approvals. The financial projections extend to 2045, indicating long-term commercialization plans for Galafold, Pombiliti + Opfolda, and potential risk-adjusted revenues for DMX-200 in FSGS and MLN.

Management Comments

• Mr. Campbell expressed concern that BioMarin might lose interest in a potential transaction with Amicus due to the recent increase in Amicus stock price and the lack of resolution of the Lupin Litigation.
• Amicus believes the claims asserted in the Complaints, the 220 Demand, and the Demand Letters are without merit.

Industry Context

StockSavvy.ai notes that the biopharmaceutical industry frequently sees strategic mergers and acquisitions, especially for companies with specialized rare disease portfolios like Amicus. The multiple stockholder lawsuits challenging proxy disclosures are a common, albeit disruptive, feature in such transactions, reflecting increased scrutiny on deal terms and valuation methodologies. The resolution of generic litigation for Galafold indicates a strategic move to secure future revenue streams, a critical factor in M&A valuations within the pharmaceutical sector.

Comparison to Industry Standards

• Centerview's Selected Public Company Analysis showed Amicus's implied per share equity value range of $7.25 to $11.95, which is below the merger consideration of $14.50 per share. This suggests the merger consideration offers a premium compared to current public company valuations.
• Centerview's Selected Precedent Transaction Analysis yielded an implied equity value per share of $9.00 to $16.25, indicating the merger consideration of $14.50 falls within this range, suggesting it is in line with or slightly above historical transaction multiples.
• Centerview's Precedent Premia Paid Analysis, applying a 30% to 80% premium to Amicus's unaffected share price of $10.89, resulted in an implied price range of $14.15 to $19.60. The merger consideration of $14.50 is at the lower end of this premium range, suggesting a reasonable, but not exceptionally high, premium compared to similar transactions.
• Goldman Sachs's Illustrative Discounted Cash Flow Analysis provided a range of $11.77 to $14.70 per share, with the merger consideration of $14.50 falling within the upper end of this valuation.
• The transaction values and premiums observed in the precedent transactions (e.g., Avadel Pharmaceuticals plc acquired by Alkermes plc at 32.9% premium, Global Blood Therapeutics, Inc. acquired by Pfizer Inc. at 102.0% premium) provide a benchmark for the Amicus-BioMarin deal, suggesting the premium offered is within the typical range for biopharmaceutical acquisitions.

Corporate Governance

Legal Proceedings

• Ramesh Pathak v. Amicus Therapeutics, Inc., et al. (Case No. 26-cv-755, U.S. District Court for the Northern District of Illinois, filed Jan 22, 2026, amended Jan 23, 2026): Alleges preliminary proxy statement omits material information and contains misleading disclosures, violating Section 14(a) and 20(a) of the Exchange Act and Rule 14a-9.
• John Marino v. Amicus Therapeutics, Inc., et al. (Index No. 650728/2026, Supreme Court of the State of New York, County of New York, filed Feb 5, 2026): Asserts claims under New York common law, alleging definitive proxy statement omits material information and contains misleading disclosures.
• Richard Lawrence v. Amicus Therapeutics, Inc., et al. (Index No. 650760/2026, Supreme Court of the State of New York, County of New York, filed Feb 6, 2026): Asserts claims under New York common law, alleging definitive proxy statement omits material information and contains misleading disclosures.
• Drulias v Bleil et al. (Case No. ATL-C-000013-26, Superior Court of the State of New Jersey, Atlantic County, filed Feb 13, 2026): Asserts claims under the New Jersey Uniform Securities Law and New Jersey common law, alleging definitive proxy statement omits material information and contains misleading disclosures.
• All lawsuits seek injunctive relief preventing merger consummation, rescission or damages if consummated, and plaintiffs' fees and expenses.
• Amicus received a demand to inspect books and records (Section 220 DGCL) and additional demand letters from purported stockholders seeking additional disclosures.
• Amicus believes all claims are without merit.

Stakeholder Impact

• Shareholders: Directly impacted by the proposed merger consideration of $14.50 per share and the ongoing legal challenges that could affect the merger's consummation or terms. The supplemental disclosures aim to provide more information for their voting decision.
• Employees: Relationships could be affected by the merger, as BioMarin may not realize the potential benefits of the transaction, potentially leading to integration challenges.
• Customers: Potential impact from the merger and the resolution of generic drug litigation for Galafold, which could affect long-term product availability and pricing dynamics.
• Creditors: Impacted by the company's net debt position and the financial implications of the merger.

Next Steps

• Stockholders are urged to submit proxies for the Special Meeting.
• Special Meeting of Stockholders to be held virtually on March 3, 2026, to vote on the Merger Agreement.
• Amicus will continue to work towards and agree to a settlement with Lupin.
• Potential for additional demands or lawsuits related to the transactions.

Key Dates

Recommendation

The stock is currently subject to a definitive merger agreement, implying a fixed acquisition price. While the financial analyses from Centerview and Goldman Sachs generally support the merger consideration, the multiple ongoing stockholder lawsuits introduce significant uncertainty regarding the timely consummation of the deal. Investors should hold pending the resolution of these legal challenges and the stockholder vote, as the outcome could impact the finalization of the merger or lead to potential delays or renegotiations.

Keywords

Amicus Therapeutics, BioMarin Pharmaceutical, Merger Agreement, Proxy Statement, SEC Filing, DEFA14A, Stockholder Lawsuits, Financial Projections, Galafold, Pombiliti + Opfolda, DMX-200, Fabry disease, FSGS, MLN, Biopharmaceutical, Rare Disease, Acquisition, Corporate Governance, Risk Factors